

| <u>MA (EU) number</u> | <u>(Invented) name</u> | <u>Strength</u> | <u>Pharmaceutical form</u> | <u>Route of administration</u> | <u>Immediate Packaging</u> | <u>Content (concentration)</u> | <u>Pack size</u> |
|------------------------------|-------------------------------|------------------------|-----------------------------------|---------------------------------------|-----------------------------------|---------------------------------------|--------------------------------|
| EU/1/21/1529/002 | Vaxzevria | --1 | Suspension for injection | Intramuscular use | Vial (glass) | 5 ml (10 doses of 0.5 ml) | 10 multidose vials (100 doses) |

¹One dose (0.5 mL) contains:

Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)*, not less than 2.5×10^8 infectious units (Inf.U)

* Produced in genetically modified human embryonic kidney (HEK) 293 cells and by recombinant DNA technology.